BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains

Boris DeCourt, Amanda Gonzales, Thomas G. Beach, Michael Malek-Ahmadi, Aaron Walker, Lucia Sue, Douglas G. Walker, Marwan N. Sabbagh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The APOE genotype is a known susceptibility factor for Alzheimer's disease (AD). It is apparent that the presence of the APOE e{open}4 allele increases the risk for developing AD, lowers the age of onset in AD, and may influence the pathological burden seen in AD. In this study, we asked whether BACE1 levels differ by APOE genotype in the AD and non-demented (ND) brain. We isolated mid-frontal cortex (MFC) and mid-temporal cortex (MTC) from post-mortem ND and AD subjects that were APOE e{open}3/3, e{open}3/4, e{open}4/4 carriers. All AD subjects met NINDS-ADRDA and NIA-Reagan criteria for a diagnosis of AD. The MFC and MTC were homogenized and the lysates underwent ELISA and Western blotting for BACE1. The ELISA revealed that total BACE1 levels were lower in the MFC of AD compared to ND subjects. Furthermore, in APOE e{open}4 carriers BACE1 levels were lower than e{open}3/3 carriers in the ND frontal cortex. No difference in BACE1 levels was observed in AD MFC and in ND and AD MTC tissues. The ELISA results were confirmed by Western blotting. Our data suggest that brain BACEl levels may be influenced by the apolipoprotein E genotype before the onset of AD, providing an alternative explanation for the lower amyloid beta 42 levels in CSF in ND and AD subjects.

Original languageEnglish (US)
Pages (from-to)309-315
Number of pages7
JournalCurrent Alzheimer Research
Volume10
Issue number3
DOIs
StatePublished - May 3 2013
Externally publishedYes

Fingerprint

Alzheimer Disease
Genotype
Brain
Frontal Lobe
Temporal Lobe
Enzyme-Linked Immunosorbent Assay
Western Blotting
National Institute of Neurological Disorders and Stroke
Apolipoproteins E
Age of Onset
Amyloid
Alleles

Keywords

  • Alzheimer's disease
  • APOE
  • BACE1
  • Brain
  • ELISA
  • Frontal cortex

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

DeCourt, B., Gonzales, A., Beach, T. G., Malek-Ahmadi, M., Walker, A., Sue, L., ... Sabbagh, M. N. (2013). BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains. Current Alzheimer Research, 10(3), 309-315. https://doi.org/10.2174/1567205011310030010

BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains. / DeCourt, Boris; Gonzales, Amanda; Beach, Thomas G.; Malek-Ahmadi, Michael; Walker, Aaron; Sue, Lucia; Walker, Douglas G.; Sabbagh, Marwan N.

In: Current Alzheimer Research, Vol. 10, No. 3, 03.05.2013, p. 309-315.

Research output: Contribution to journalArticle

DeCourt, B, Gonzales, A, Beach, TG, Malek-Ahmadi, M, Walker, A, Sue, L, Walker, DG & Sabbagh, MN 2013, 'BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains', Current Alzheimer Research, vol. 10, no. 3, pp. 309-315. https://doi.org/10.2174/1567205011310030010
DeCourt B, Gonzales A, Beach TG, Malek-Ahmadi M, Walker A, Sue L et al. BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains. Current Alzheimer Research. 2013 May 3;10(3):309-315. https://doi.org/10.2174/1567205011310030010
DeCourt, Boris ; Gonzales, Amanda ; Beach, Thomas G. ; Malek-Ahmadi, Michael ; Walker, Aaron ; Sue, Lucia ; Walker, Douglas G. ; Sabbagh, Marwan N. / BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains. In: Current Alzheimer Research. 2013 ; Vol. 10, No. 3. pp. 309-315.
@article{ca926ace2cd54e188efc0d7d50e4fa9e,
title = "BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains",
abstract = "The APOE genotype is a known susceptibility factor for Alzheimer's disease (AD). It is apparent that the presence of the APOE e{open}4 allele increases the risk for developing AD, lowers the age of onset in AD, and may influence the pathological burden seen in AD. In this study, we asked whether BACE1 levels differ by APOE genotype in the AD and non-demented (ND) brain. We isolated mid-frontal cortex (MFC) and mid-temporal cortex (MTC) from post-mortem ND and AD subjects that were APOE e{open}3/3, e{open}3/4, e{open}4/4 carriers. All AD subjects met NINDS-ADRDA and NIA-Reagan criteria for a diagnosis of AD. The MFC and MTC were homogenized and the lysates underwent ELISA and Western blotting for BACE1. The ELISA revealed that total BACE1 levels were lower in the MFC of AD compared to ND subjects. Furthermore, in APOE e{open}4 carriers BACE1 levels were lower than e{open}3/3 carriers in the ND frontal cortex. No difference in BACE1 levels was observed in AD MFC and in ND and AD MTC tissues. The ELISA results were confirmed by Western blotting. Our data suggest that brain BACEl levels may be influenced by the apolipoprotein E genotype before the onset of AD, providing an alternative explanation for the lower amyloid beta 42 levels in CSF in ND and AD subjects.",
keywords = "Alzheimer's disease, APOE, BACE1, Brain, ELISA, Frontal cortex",
author = "Boris DeCourt and Amanda Gonzales and Beach, {Thomas G.} and Michael Malek-Ahmadi and Aaron Walker and Lucia Sue and Walker, {Douglas G.} and Sabbagh, {Marwan N.}",
year = "2013",
month = "5",
day = "3",
doi = "10.2174/1567205011310030010",
language = "English (US)",
volume = "10",
pages = "309--315",
journal = "Current Alzheimer Research",
issn = "1567-2050",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains

AU - DeCourt, Boris

AU - Gonzales, Amanda

AU - Beach, Thomas G.

AU - Malek-Ahmadi, Michael

AU - Walker, Aaron

AU - Sue, Lucia

AU - Walker, Douglas G.

AU - Sabbagh, Marwan N.

PY - 2013/5/3

Y1 - 2013/5/3

N2 - The APOE genotype is a known susceptibility factor for Alzheimer's disease (AD). It is apparent that the presence of the APOE e{open}4 allele increases the risk for developing AD, lowers the age of onset in AD, and may influence the pathological burden seen in AD. In this study, we asked whether BACE1 levels differ by APOE genotype in the AD and non-demented (ND) brain. We isolated mid-frontal cortex (MFC) and mid-temporal cortex (MTC) from post-mortem ND and AD subjects that were APOE e{open}3/3, e{open}3/4, e{open}4/4 carriers. All AD subjects met NINDS-ADRDA and NIA-Reagan criteria for a diagnosis of AD. The MFC and MTC were homogenized and the lysates underwent ELISA and Western blotting for BACE1. The ELISA revealed that total BACE1 levels were lower in the MFC of AD compared to ND subjects. Furthermore, in APOE e{open}4 carriers BACE1 levels were lower than e{open}3/3 carriers in the ND frontal cortex. No difference in BACE1 levels was observed in AD MFC and in ND and AD MTC tissues. The ELISA results were confirmed by Western blotting. Our data suggest that brain BACEl levels may be influenced by the apolipoprotein E genotype before the onset of AD, providing an alternative explanation for the lower amyloid beta 42 levels in CSF in ND and AD subjects.

AB - The APOE genotype is a known susceptibility factor for Alzheimer's disease (AD). It is apparent that the presence of the APOE e{open}4 allele increases the risk for developing AD, lowers the age of onset in AD, and may influence the pathological burden seen in AD. In this study, we asked whether BACE1 levels differ by APOE genotype in the AD and non-demented (ND) brain. We isolated mid-frontal cortex (MFC) and mid-temporal cortex (MTC) from post-mortem ND and AD subjects that were APOE e{open}3/3, e{open}3/4, e{open}4/4 carriers. All AD subjects met NINDS-ADRDA and NIA-Reagan criteria for a diagnosis of AD. The MFC and MTC were homogenized and the lysates underwent ELISA and Western blotting for BACE1. The ELISA revealed that total BACE1 levels were lower in the MFC of AD compared to ND subjects. Furthermore, in APOE e{open}4 carriers BACE1 levels were lower than e{open}3/3 carriers in the ND frontal cortex. No difference in BACE1 levels was observed in AD MFC and in ND and AD MTC tissues. The ELISA results were confirmed by Western blotting. Our data suggest that brain BACEl levels may be influenced by the apolipoprotein E genotype before the onset of AD, providing an alternative explanation for the lower amyloid beta 42 levels in CSF in ND and AD subjects.

KW - Alzheimer's disease

KW - APOE

KW - BACE1

KW - Brain

KW - ELISA

KW - Frontal cortex

UR - http://www.scopus.com/inward/record.url?scp=84876878855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876878855&partnerID=8YFLogxK

U2 - 10.2174/1567205011310030010

DO - 10.2174/1567205011310030010

M3 - Article

VL - 10

SP - 309

EP - 315

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1567-2050

IS - 3

ER -